Clopidogrel hyporesponsiveness and the FDA boxed warning: Detection and management of patients with genetic polymorphisms

被引：6
|
作者：
Perry, Elizabeth [1 ]
机构：
[1] Univ Louisiana, Monroe Coll Pharm, Shreveport, LA 71103 USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2011年 / 68卷 / 06期
关键词：
PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PRASUGREL; THROMBOLYSIS; INHIBITION; COMMON;
D O I：
10.2146/ajhp100422
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：529 / 532
页数：4
相关论文
共 39 条
  • [21] Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population
    K. Subraja
    S. A. Dkhar
    R. Priyadharsini
    B. K. Ravindra
    D. G. Shewade
    S. Satheesh
    M. G. Sridhar
    S. K. Narayan
    C. Adithan
    European Journal of Clinical Pharmacology, 2013, 69 : 415 - 422
  • [22] Clopidogrel efficacy after percutaneous coronary interventions considering with cyp2c19 genetic polymorphisms in patients with coronary heart disease
    Uzokov, J.
    Alyavi, B.
    Abdullaev, A.
    Rasulov, Y.
    Ortikov, J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52
  • [23] Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population
    Subraja, K.
    Dkhar, S. A.
    Priyadharsini, R.
    Ravindra, B. K.
    Shewade, D. G.
    Satheesh, S.
    Sridhar, M. G.
    Narayan, S. K.
    Adithan, C.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (03) : 415 - 422
  • [24] CLOPIDOGREL EFFICACY AFTER PERCUTANEOUS CORONARY INTERVENTIONS CONSIDERING WITH CYP2C19 GENETIC POLYMORPHISMS IN PATIENTS WITH CORONARY HEART DISEASE
    Uzokov, J.
    Alyavi, B.
    Abdullaev, A.
    Orziev, D.
    Madjitov, I.
    ATHEROSCLEROSIS, 2022, 355 : E276 - E276
  • [25] Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI
    Erathi, Harsha V.
    Durgaprasad, Rajasekhar
    Velam, Vanjakshamma
    Sarma, P. V. G. K.
    Rodda, Madhavi
    Kapil, C.
    Kanavath, Sreedhar N.
    MINERVA CARDIOANGIOLOGICA, 2018, 66 (01): : 16 - 25
  • [26] ANTIPLATELET THERAPY WITH CLOPIDOGREL TAKING INTO ACCOUNT CYP2C19 GENETIC POLYMORPHISMS IN PATIENTS WITH CORONARY HEART DISEASE AFTER CORONARY ARTERY STENTING
    Uzokov, J.
    Alyavi, B.
    Abdullaev, A.
    Muxitdinova, O.
    Ubaydullaeva, Z.
    ATHEROSCLEROSIS, 2021, 331 : E265 - E265
  • [27] Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy
    Zhang, Suli
    Zhu, Jinhang
    Li, Hua
    Li, Fengzhen
    Zhu, Bin
    Li, Tao
    Fang, Shuxin
    Qin, Shengying
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (04): : 138 - 143
  • [28] Genetic polymorphisms of genes involved in oxidative stress and inflammatory management in oncopediatric patients with chemo-induced oral mucositis
    Coelho, Marina Castro
    Chagas Viana Filho, Jose Maria
    de Souza, Beatriz Fernandes
    Gondim Valenca, Ana Maria
    Persuhn, Darlene Camati
    Paulo de Oliveira, Naila Francis
    JOURNAL OF APPLIED ORAL SCIENCE, 2022, 30
  • [29] The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients
    Namazi, Soha
    Kojuri, Javad
    Khalili, Andia
    Azarpira, Negar
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (07) : 903 - 908
  • [30] Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors
    Thakur, Mugdha
    Grossman, Iris
    McCrory, Douglas C.
    Orlando, Lori A.
    Steffens, David C.
    Cline, Kathryn E.
    Gray, Rebecca N.
    Farmer, Jennifer
    DeJesus, Georgette
    O'Brien, Cara
    Samsa, Gregory
    Goldstein, David B.
    Matchar, David B.
    GENETICS IN MEDICINE, 2007, 9 (12) : 826 - 835
1234